Acne vulgaris is the most common skin condition in the U.S., affecting approximately 40 million to 50 million Americans annually. The disease ranges in severity from mild to severe cystic acne and causes both physical and psychological effects, including permanent scarring, anxiety, depression and poor self-esteem. The complexity of the disease requires treatments that address more than one of the major causes of acne pathogenesis.
SB204, the Company’s lead drug candidate for the treatment of acne vulgaris, is in late stage clinical development with Phase 3 top-line results expected in 1H 2017. We believe that SB204 has the potential to redefine the standard of care in acne vulgaris, and if approved will be the first new chemical entity specifically developed for the treatment of acne vulgaris in more than 20 years.
SB204 Clinical Trial Results
- Statistically significant efficacy with SB204 4% when compared to vehicle in both inflammatory and non-inflammatory lesion endpoints
- Clear separation between active and vehicle
- Good cutaneous tolerability
- Once daily treatment that is non-inferior to twice daily
- No measureable systemic exposure under maximal use conditions in moderate-to-severe acne patients